$FAST

Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were lower on Monday, with several companies experiencing significant drops in pre-market trading. Fastenal Co (NASDAQ: FAST) fell after reporting mixed first-quarter results, while Replimune Group Inc (NASDAQ: REPL) plunged due to an FDA decision regarding its Biologics License Application. Children's Place Inc (NASDAQ: PLCE) also saw a substantial decline after posting weaker-than-expected fourth-quarter results.

Original reporting
Benzinga · Avi Kapoor
Published Apr 13, 2026, 12:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 13, 2026, 12:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session — source image
Decision brief

The 30-second read

$FASTBearishMed
01

Why it matters

Negative pre-market movements suggest cautious trading; potential for increased volatility in affected stocks.

02

Market read

The news highlights sector-specific challenges that could influence broader market dynamics, especially in retail and biotech sectors.

03

What to watch

Potential for company-specific positive catalysts or broader economic data to offset current negative signals.

Timing: Immediate to short-term (next few trading sessions)

Background

The U.S. stock market opened lower on Monday amid concerns over earnings and regulatory news, impacting investor sentiment.

Company-level read

Ticker impact

$FASTBearishHigh confidence
Context

Significant pre-market decline following mixed quarterly results.

Expected impact

Moderate decline of 2-4% in the short term.

Evidence & confidence

Earnings miss combined with negative market sentiment suggests continued downward pressure in the near term.

$REPLBearishMedium confidence
Context

Plunged after FDA decision on biologics license application.

Expected impact

Potential further decline of 3-5% if no positive news emerges.

Evidence & confidence

Regulatory decisions can cause immediate drops; future movement depends on company response and industry sentiment.

$PLCEBearishMedium confidence
Context

Declined after weaker-than-expected quarterly results.

Expected impact

Likely short-term decline of 2-3%, with possible stabilization if fundamentals improve.

Evidence & confidence

Earnings miss suggests caution; recovery depends on future sales performance and market conditions.

Market effects

Potential weakness in retail and biotech sectors due to earnings and regulatory setbacks.

Limited to U.S. markets; minimal international influence.

Low; primarily affecting specific sectors within the U.S. stock market.

Counterpoint

Market may have already priced in these negative developments; stocks could stabilize or rebound if broader market sentiment improves.

Key entities

  • Fastenal Co

    A distributor of industrial and construction supplies.

  • Replimune Group Inc

    A biotechnology company focused on cancer immunotherapies.

  • Children's Place Inc

    A specialty retailer of children's apparel.

Related articles

$ABCLMed

Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?

AbCellera (ABCL) hit a 52-week high after Phase 2 results for ABCL635 showed an 83% reduction in symptom frequency versus 33% for placebo, and Jones Research raised its price target to $25. Replimune (REPL) reached a 52-week high on a $150M financing. Airbnb (ABNB) rose to a four-year high on Q2 results and a $4.69B-$4.77B Q3 outlook.

$REPLHighAI 9/10

Replimune Group, Inc.: Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Replimune Group (Nasdaq: REPL) reported fiscal Q1 2027 results for the quarter ended June 30, 2026 and said the FDA approved TUDRIQEV (vusolimogene oderparepvec) with nivolumab for unresectable advanced cutaneous melanoma after PD-1 progression. The company expects U.S. launch within 60 days after a $150 million financing. Cash was $195.3M; net loss was $69.8M.

$REPLHighAI 9/10

Replimune Group, Inc. (REPL): Results of Operations and Financial Condition

Replimune Group, Inc. (REPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2623208d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appoin

$REPLMedAI 9/10

Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment

Replimune Group (NasdaqGS: REPL) said the FDA granted accelerated approval for TUDRIQEV (RP1) with nivolumab to treat advanced cutaneous melanoma after prior anti-PD 1 therapy. The company described this as its first FDA approval and expects near-term commercialization, with attention shifting to confirmatory trials and related legal and regulatory matters. The article notes a recent $150m follow-on equity offering.